Research Grade Ramucirumab ( 雷莫芦单抗 )

CSD00194

>95%

1mg/ml

PBS buffer PH7.5

CHO cells

Please contact with the lab for this information.

Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.

1121B,IMC-1121B,LY3009806

KDR/CD309[Homo sapiens]

3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compounds have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. SU5408 (VEGFR2 Kinase Inhibitor I) is found to be the most potent and selective VEGFR2 inhibitor among the compounds. SU5408 (VEGFR2 Kinase Inhibitor I) shows little or no effect against receptors for platelet-derived growth factor, epidermal growth factor, or insulin-like growth factor (IC50>100 µM).

Homo sapiens

IgG1-kappa

143600.0 Da

15966-93-5

For research use only .